Drug Profile
Influenza virus vaccine - Denka Seiken
Alternative Names: DNK FLU; DNK-651Latest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator Denka Seiken
- Class Influenza virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II/III Influenza virus infections
Most Recent Events
- 28 May 2019 No recent reports of development identified for phase-I development in Influenza-virus-infections(In the elderly, Prevention, In volunteers, In adults) in Japan (Intradermal)
- 10 Dec 2018 Denka Seiken completes a phase II trial in Influenza virus infections (In volunteers, In adults, In adolescents, In children, Prevention) (Intradermal) in Japan (JapicCTI-173720)
- 01 Oct 2017 Phase-II clinical trials in Influenza virus infections (In adults, In adolescents, In children, In volunteers, Prevention) in Japan (Intradermal) (JapicCTI-173720)